Capha Pharmaceuticals Inc.
FPSUF
$0.00
$0.000.00%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.09% | 7.25% | -5.03% | -9.56% | -9.45% |
| Depreciation & Amortization | -100.00% | -100.00% | -100.00% | -100.00% | -75.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.55% | 7.21% | -5.23% | -9.71% | -9.38% |
| Operating Income | -4.55% | -7.21% | 5.23% | 9.71% | 9.38% |
| Income Before Tax | 0.00% | -4.53% | 13.28% | 8.73% | 8.93% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 0.00% | -4.53% | 13.28% | 8.73% | 8.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 0.00% | -4.53% | 13.28% | 8.73% | 8.93% |
| EBIT | -4.55% | -7.21% | 5.23% | 9.71% | 9.38% |
| EBITDA | -5.09% | -7.25% | 5.03% | 9.56% | 9.45% |
| EPS Basic | 0.00% | 0.00% | 11.11% | 11.11% | 11.11% |
| Normalized Basic EPS | 0.00% | 20.00% | 33.33% | 33.33% | 33.33% |
| EPS Diluted | 0.00% | 0.00% | 11.11% | 11.11% | 11.11% |
| Normalized Diluted EPS | 0.00% | 20.00% | 33.33% | 33.33% | 33.33% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |